- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Nov 14, 2024
Deals
Already partners on bispecific, BioNTech buys Biotheus for $800M
Along with potential Keytruda competitor, German biotech gains pipeline, bispecific platform, and China sites via acquisition
BioCentury | Feb 3, 2024
Discovery & Translation
Science spotlight: RNA-based enzymes for DNA editing; plus XIST-driven autoimmunity and more
BioCentury’s roundup of translational innovations
BioCentury | Feb 11, 2022
Distillery Therapeutics
Phenotype-guided identification of small molecules for fibrosis
BioCentury | Nov 3, 2021
Emerging Company Profile
Parthenon: Bringing down immune exclusion in cancer
Northpond and Pfizer, Taiho VC affiliates back $65M series A for newco exploring largely uncharted area of tumor immunotherapy biology
BioCentury | Sep 1, 2021
Product Development
Poseida gains proof of concept for solid tumor CAR T
Prostate cancer data a scientific step forward for CAR Ts, but don’t guarantee a market for the cells
BioCentury | Jul 17, 2021
Finance
To Hong Kong via the Caymans, Maryland siRNA play Sirnaomics looks to list at last
Patrick Lu’s company cuts trail to Hong Kong IPO by re-incorporating ex-U.S.
BioCentury | Jul 7, 2021
Product Development
July 6 Quick Takes: Ocugen eyes BLA following Phase III COVID vaccine readout; plus SCOTUS, Provention, British Patient Capital and more
The COVAXIN COVID-19 vaccine from Ocugen Inc. was 77.8% effective against symptomatic disease and 93.4% effective against severe infection in a Phase III study in India, building the case for approval
BioCentury | Jun 5, 2021
Product Development
Fusion proteins lead in TGFβ blockade at ASCO21: Data Byte
Among nine TGFβ-targeting programs with presentations at ASCO21, nearly all have a dual targeting strategy, and five are testing the hypothesis that targeting the immunosuppressive cytokine
BioCentury | Aug 26, 2020
Deals
Aug. 25 Quick Takes: A slew of private financings led by Connect’s $115M series C; plus BMS-Forbius, Takeda deals, Bio-Thera-BeiGene and adds to HKSE, NASDAQ queues
Connect raises $115M C round, eyes pivotal trialsRA Capital’s Derek DiRocco will join the board of Suzhou Connect Biopharmaceuticals Ltd. after the firm led the Chinese biotech’s
BioCentury | Aug 14, 2020
Translation in Brief
Hesperos applies organ-on-a-chip tech to ALS, Sinopharm details interim COVID-19 vaccine readout and more
BioCentury’s roundup of translational news
Items per page:
1 - 10 of 149